Deals this week: Guiyang Xintian Pharmaceutical, TetraGenetics, Magenta Therapeutics

4th May 2017 (Last Updated May 4th, 2017 18:30)

Chinese pharmaceutical company Guiyang Xintian Pharmaceutical has announced the pricing for its proposed initial public offering (IPO) of shares to raise ¥317.02m ($46m) in gross proceeds.

Chinese pharmaceutical company Guiyang Xintian Pharmaceutical has announced the pricing for its proposed initial public offering (IPO) of shares to raise ¥317.02m ($46m) in gross proceeds.

Under the IPO, the company will issue 17.22 million shares priced at ¥18.41 ($2.67) each.

US-based biopharmaceutical company TetraGenetics has announced that it has secured venture funding from JDRF T1D Fund in order to expedite the development of a type 1 diabetes immunotherapy.

Magenta Therapeutics has completed a series B financing round to raise $50m, which will be utilised to develop product candidates in transplantation medicines used for a more precise preparation of patients, as well as stem cell harvesting and expansion.

Magenta Therapeutics is a biotechnology company based in the US.

"US-based biopharmaceutical company TetraGenetics has announced that it has secured venture funding from JDRF T1D Fund in order to expedite the development of a type 1 diabetes immunotherapy."

ImCheck Therapeutics has raised €20m ($21.8m) in a series A venture financing round led by Boehringer Ingelheim Venture Fund (BIVF), Kurma Partners and Idinvest Partners, and participated in by Gimv NV and Life Sciences Partners.

Based in France, ImCheck Therapeutics develops biotherapies for immune-oncology.

The proceeds from the venture financing round are intended to be used to advance the development of a number of drug candidates and begin clinical trials by 2018.

US-based pulmonary drug developer Savara intends to raise $18m in gross proceeds through a public offering of shares.

The proceeds are intended to be used for working capital and general corporate purposes.